Entropy Technologies LP Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

Entropy Technologies LP purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 37,850 shares of the biotechnology company's stock, valued at approximately $757,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ADMA. Sei Investments Co. lifted its position in shares of ADMA Biologics by 176.0% during the first quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company's stock worth $2,597,000 after purchasing an additional 250,925 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of ADMA Biologics by 90.7% in the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company's stock valued at $7,717,000 after purchasing an additional 556,175 shares during the period. ProShare Advisors LLC boosted its holdings in shares of ADMA Biologics by 9.2% in the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company's stock valued at $358,000 after buying an additional 4,570 shares during the period. Hillsdale Investment Management Inc. raised its holdings in shares of ADMA Biologics by 41,893.3% during the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company's stock worth $4,157,000 after acquiring an additional 628,400 shares during the period. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of ADMA Biologics by 114.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company's stock valued at $357,000 after purchasing an additional 28,832 shares during the period. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ADMA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded down $1.16 during mid-day trading on Friday, reaching $19.04. The company had a trading volume of 3,623,937 shares, compared to its average volume of 3,667,049. The business's 50-day simple moving average is $18.49 and its 200 day simple moving average is $14.26. The firm has a market cap of $4.44 billion, a price-to-earnings ratio of 68.00 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the business posted $0.01 EPS. On average, research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 10.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 in the last quarter. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.